rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

HeartSciences Inc.

HSCS · Nasdaq

Health CareMedical DevicesIn trendAI

HSCS stood above a rising 150-day average in 6 of the last 52 weekly readings, including each of the last 6 weeks. It is 19.6% above that average now. Medical Devices: 29% of its 181 stocks in an uptrend (−4 points in four weeks); Health Care: 27% (−6 points in four weeks).

Statistics

Last close, 22 Oct 2026
3.17 −10.96%
52-week range
—
Volume
0.10M
Average volume (50 days)
—
Relative volume
—
Rotation
In trend
Weeks in an uptrend
6 in a row
Industry in uptrend
29% -4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
16 (+5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 6 of 52 weeks.

24 Apr – 23 Oct
19%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Price and volume

$2.99$4.11$5.2311 Sep23 Sep2 Oct13 Oct22 Oct
close

Daily bars to 22 Oct 2026: 29 sessions (1Y reaches back before the first session held here, 11 Sep 2026, so this is all of them). 1D is the last two sessions and 1W the last week of the same daily bars; nothing here is intraday.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$15K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders16+5 on the quarter
New · exited8 · 3
Reported value$386K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
TFB Advisors LLCunchanged · filed 6 Aug 202629,740$75K00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202623,049$58K-5,889−20.4%
Astoria Strategic Wealth, Inc.unchanged · filed 16 Jul 202618,927$48K00.0%
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 202617,968$45K+17,968
VANGUARD FIDUCIARY TRUST COnew · filed 13 Aug 202617,239$43K+17,239
Tradition Wealth Management, LLCunchanged · filed 11 Aug 202616,819$42K00.0%
CITADEL ADVISORS LLCnew · filed 14 Aug 202614,488$36K+14,488
CITIGROUP INCnew · filed 3 Aug 20265,859$15K+5,859
UBS Group AGreduced · filed 13 Aug 20265,812$15K-664−10.3%
Tower Research Capital LLC (TRC)reduced · filed 11 Aug 20261,568$3,936-483−23.5%
31 Mar 2023 – 30 Jun 2026
41321Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Danielle Watson Company insiderOfficer · last 7 Jul 20260 · 0
Andrew Simpson Company insiderDirector, Officer · last 22 Jun 20260 · 0
Bruce Bent Company insiderDirector · last 12 Jan 20260 · 0
David R. Wells Company insiderDirector · last 12 Jan 20260 · 0
Brian Szymczak Company insiderDirector · last 22 Dec 20250 · 0
Mark T. Hilz Company insiderOfficer · last 22 Dec 20250 · 1

Same industry

RCEL Avita MedicalLeading+126%
HTFL HeartflowLeading+59%
ATRC AtriCureLeading+53%
HAE HaemoneticsLeading+45%
SIBN Si-BoneLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2026 · to 30 Apr 202659.1%
Share count trendFY 2026 · to 20 Jul 202622.3%
Cash and equivalentsFY 2026 · to 30 Jun 2026$1.7M
Free cash flowFY 2026 · to 30 Apr 2026−$7.4M

Analyst forecasts

No analyst forecasts yet.